Impact of discontinuing fluoroquinolone prophylaxis on early mortality after allogeneic marrow or peripheral blood SCT with myeloablative conditioning.
Kanda
J
J
Ichinohe
T
T
Saito
T
T
Yamashita
K
K
Kondo
T
T
Ishikawa
T
T
Ichiyama
S
S
Uchiyama
T
T
D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000209:etiology; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods / Q000401:mortality; D024841:Fluoroquinolones / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods / Q000401:mortality; D011292:Premedication; D012189:Retrospective Studies; D056737:Safety-Based Drug Withdrawals; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods / Q000401:mortality*; D014184:Transplantation, Homologous; D055815:Young Adult
D024841:Fluoroquinolones; D019653:Myeloablative Agonists